- Home
- FTLF vs CHRS Comparison
FTLF vs CHRS Comparison
Compare FTLF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTLF
- CHRS
- Stock Information
- Founded
- FTLF 2005
- CHRS 2010
- Country
- FTLF United States
- CHRS United States
- Employees
- FTLF N/A
- CHRS N/A
- Industry
- FTLF Medicinal Chemicals and Botanical Products
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTLF Health Care
- CHRS Health Care
- Exchange
- FTLF Nasdaq
- CHRS Nasdaq
- Market Cap
- FTLF 145.8M
- CHRS 134.4M
- IPO Year
- FTLF N/A
- CHRS 2014
- Fundamental
- Price
- FTLF $15.44
- CHRS $1.07
- Analyst Decision
- FTLF Strong Buy
- CHRS Strong Buy
- Analyst Count
- FTLF 1
- CHRS 4
- Target Price
- FTLF $20.00
- CHRS $5.38
- AVG Volume (30 Days)
- FTLF 15.2K
- CHRS 2.0M
- Earning Date
- FTLF 03-04-2025
- CHRS 03-12-2025
- Dividend Yield
- FTLF N/A
- CHRS N/A
- EPS Growth
- FTLF 93.67
- CHRS N/A
- EPS
- FTLF 0.85
- CHRS N/A
- Revenue
- FTLF $62,755,000.00
- CHRS $304,340,000.00
- Revenue This Year
- FTLF $25.54
- CHRS $2.07
- Revenue Next Year
- FTLF $7.30
- CHRS N/A
- P/E Ratio
- FTLF $18.16
- CHRS N/A
- Revenue Growth
- FTLF 40.17
- CHRS 44.19
- 52 Week Low
- FTLF $10.51
- CHRS $0.66
- 52 Week High
- FTLF $17.75
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- FTLF 49.41
- CHRS 39.03
- Support Level
- FTLF $14.75
- CHRS $1.06
- Resistance Level
- FTLF $15.49
- CHRS $1.16
- Average True Range (ATR)
- FTLF 0.63
- CHRS 0.08
- MACD
- FTLF 0.00
- CHRS 0.00
- Stochastic Oscillator
- FTLF 35.29
- CHRS 5.56
About FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, and sports drink products, meal replacement products and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products and Supplements.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.